Solventum Corporation (NYSE:SOLV - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $90.45 and last traded at $90.4460, with a volume of 50878 shares changing hands. The stock had previously closed at $89.57.

Analysts Set New Price Targets

• Solventum Nears Inflection Point As It Begins to Unlock Value

A number of research analysts have recently weighed in on SOLV shares. Weiss Ratings upgraded Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Piper Sandler boosted their target price on Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th. KeyCorp raised their price target on Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Finally, Stifel Nicolaus lifted their price objective on Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $91.64.

Check Out Our Latest Stock Report on Solventum

Solventum Stock Up 0.9%

• Target the Red-Hot Spin-Off and Merger Space With These ETFs

The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The company's 50-day simple moving average is $80.91 and its 200 day simple moving average is $75.03. The firm has a market cap of $15.38 billion, a P/E ratio of 11.04, a price-to-earnings-growth ratio of 1.15 and a beta of 0.60.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business's quarterly revenue was up 2.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Research analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Solventum

• Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SOLV. California State Teachers Retirement System grew its stake in shares of Solventum by 5,434.1% during the second quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company's stock valued at $1,021,075,000 after buying an additional 12,995,776 shares during the last quarter. Independent Franchise Partners LLP boosted its position in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock valued at $1,216,785,000 after buying an additional 2,456,451 shares during the period. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Solventum in the 2nd quarter worth about $150,066,000. Norges Bank bought a new position in Solventum in the 4th quarter worth about $147,467,000. Finally, Diamond Hill Capital Management Inc. increased its position in shares of Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company's stock worth $167,119,000 after acquiring an additional 1,272,921 shares during the period.

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Read More

• Five stocks we like better than Solventum
• If Boeing Ramps Up Production, These Suppliers May Win Big
• Marvell Takes a Shot a Broadcom's Throne With Google Deal
• 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's Why
• Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Solventum Right Now?

Before you consider Solventum, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.

While Solventum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here